title: Heparin-binding EGF-like growth factor modulation by antiprogestin and CG in the baboon (Papio anubis).
abstract: The objectives of this study were to determine whether antiprogestin therapy or the infusion of human CG to mimic blastocyst transit in the baboon alters heparin-binding EGF-like growth factor expression during the window of implantation. During the menstrual cycle, heparin-binding EGF-like growth factor protein accumulation in the glandular epithelium was low in the proliferative phase and increased to maximal expression on d 5 and 10 postovulation. Stromal cells accumulated high levels of heparin-binding EGF-like growth factor in the proliferative phase, which decreased by d 5 postovulation. These transitional changes in both cell types were delayed when cycling baboons were treated with the antiprogestin ZK 137.316 during the luteal phase. The treatment with human CG had no effect on expression of heparin-binding EGF-like growth factor when compared with cycling baboons on d 10 postovulation and was comparable with that observed on d 18 and 22 of pregnancy. However, the superimposition of the antiprogestin with the human CG treatment also decreased expression in the epithelial cells. In summary, heparin-binding EGF-like growth factor accumulation in the epithelial glands is under the influence of progesterone and does not seem to be influenced by the paracrine secretion of trophoblast CG.
authors.affiliation: Department of Obstetrics and Gynecology, C. S. Mott Center for Human Growth and Development, Wayne State University, Detroit, Michigan, USA.
authors.forename: R E
authors.initials: RE
authors.lastname: Leach
authors.forename: R
authors.initials: R
authors.lastname: Khalifa
authors.forename: D R
authors.initials: DR
authors.lastname: Armant
authors.forename: A
authors.initials: A
authors.lastname: Brudney
authors.forename: S K
authors.initials: SK
authors.lastname: Das
authors.forename: S K
authors.initials: SK
authors.lastname: Dey
authors.forename: A T
authors.initials: AT
authors.lastname: Fazleabas
mesh_terms: D000818:Animals; D001755:Blastocyst / Q000187:drug effects; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D010064:Embryo Implantation / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000096:biosynthesis*; D005260:Female; D066257:Heparin-binding EGF-like Growth Factor; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D036341:Intercellular Signaling Peptides and Proteins; D010215:Papio / Q000502:physiology*; D019899:Paracrine Communication / Q000187:drug effects / Q000502:physiology; D011247:Pregnancy; D011374:Progesterone / Q000494:pharmacology; D011372:Progestins / Q000037:antagonists & inhibitors*; D015347:RNA Probes / Q000494:pharmacology; D013256:Steroids / Q000494:pharmacology; D017154:Stromal Cells / Q000187:drug effects
chemical_list: C422565:13beta-methyl 19-nor-steroid; D006063:Chorionic Gonadotropin; C587883:HBEGF protein, human; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D011372:Progestins; D015347:RNA Probes; D013256:Steroids; D011374:Progesterone; D004815:Epidermal Growth Factor